Orasis Pharmaceuticals, a leading ophthalmic company focused on advancing vision care, has announced the introduction of Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4% Starter Packs to provide patients with more flexible options for managing presbyopia and to allow eye care professionals to gain first-hand experience with the therapy. The new Starter Packs represent the next step in Qlosi’s commercial rollout, following its U.S. launch in April 2025, which has seen strong adoption among prescribing clinicians and higher-than-expected refill rates, with no serious adverse events reported to date.

Health Technology Insights: Health Technology Insights: Latest News And Innovations – Roundup 4 November 2025

Elad Kedar, Chief Executive Officer of Orasis Pharmaceuticals, highlighted the company’s commitment to changing the way presbyopia is treated. He explained that Qlosi offers an alternative to traditional reading glasses, and that Orasis’ direct-to-consumer campaigns have generated over one million engagements so far. Kedar emphasized that the introduction of Starter Packs builds on this momentum, supporting both patient adoption and market growth as the company plans to expand its efforts further in 2026.

Each Qlosi Starter Pack contains ten vials, providing two doses per day for five days, along with a patient progress tracker and a referral card, all shipped directly to the prescribing eye care professional. The packs are designed to simplify the introduction of Qlosi to patients and to facilitate meaningful discussions on presbyopia management.

Health Technology Insights: Mirum Pharma showcases LIVMARLI and Volixibat data at AASLD

Paul Karpecki, OD, FAAO, Director of Cornea and External Disease at Kentucky Eye Institute and Associate Professor at University of Pikeville, Kentucky College of Optometry, shared that Qlosi has transformed conversations with patients about presbyopia. He noted that many patients are surprised an eye drop can improve near vision and that the Starter Packs make it easier to get patients started on this new treatment option.

Qlosi is the only FDA-approved eye drop formulated with the lowest effective concentration of pilocarpine for optimal results. Its proprietary EyeQ Formulation is designed for comfort while maintaining pupil size, enhancing depth of focus, and improving near vision without compromising distance or night vision. Clinical trials have confirmed its favorable safety profile with no serious side effects observed.

This launch reflects Orasis’ dedication to providing innovative, practical solutions for presbyopia, giving both patients and eye care professionals new tools to improve visual outcomes while maintaining safety and comfort.

Health Technology Insights: Gilead’s Livdelzi Shows ALP Reduction and Itch Relief in PBC

To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com